Experimental prostate cancer drug trial halted early
NCT ID NCT03843918
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study tested a new drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to hormone therapy. The goal was to check safety and find the right dose, and later see if it could lower PSA levels. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan Cancer Hospital
Shanghai, Shanghai Municipality, China
-
ZheJiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.